KOSDAQBiotech & Pharma389030

Geninus

₩2,095 0.00%2026-10-02 close

Market Cap

₩82.3B

Turnover

₩300M

Volume

170,000 shares

Shares out.

39.4M

PER

—

PBR

1.4×

EPS

-₩598

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

Japan Contracts Rise as Capital Base Is Rebuilt

Geninus is seeing revenue recovery driven by its Japanese subsidiary GxD's contract wins, while accumulated losses and capital impairment risk were addressed through a preferred-stock investment last year.

1
2025 revenue rose 62% year-on-year to KRW 10.48bn, but operating loss widened to KRW 11.67bn and net loss to KRW 17.37bn
2
Japanese subsidiary GxD is driving overseas revenue via the SCRUM-Japan project, with the company projecting GxD's 2026 revenue to grow more than 80% year-on-year
3
In March 2026 the company secured a KRW 20bn convertible preferred share investment from KB Investment and Company K Partners, resolving capital impairment and administrative-issue designation risk
4
Net loss attributable to owners over the latest four quarters through 2026Q2 reached KRW 20.36bn, already exceeding full-year 2025 losses, showing losses remain persistent
5
The company is shifting its business model from NGS services toward an AI drug-discovery platform (IntelliMed) based on single-cell and spatial omics, though this transition remains at an early stage

Business structure

Geninus was spun off from Samsung Medical Center's Samsung Genome Institute in 2018 and listed on KOSDAQ in November 2021 as a genomics analysis and AI drug-discovery platform company.

Its core offerings are the next-generation-sequencing (NGS) based cancer genomic diagnostic solution CancerSCAN and the liquid biopsy test LiquidSCAN, supplied mainly to major domestic tertiary hospitals including Samsung Medical Center.

The company also operates the ultra-precision single-cell analysis platform Celinus, and has recently upgraded, in collaboration with Amazon Web Services, a multi-omics pathology analysis platform called SpaceInsight.

Since March the company has restructured its business toward AI analysis solutions and pharmaceutical data services, scaling back NGS-based analysis and focusing on higher value-added AI solutions such as IntelliMed and SpaceInsight.

In July 2023 it established a wholly owned Japanese subsidiary, GxD, to serve as a base for genomic AI drug-development solutions targeting major Japanese pharmaceutical companies.

In drug discovery, the company runs the AI platform IntelliMed, built on its genomic database CASOD, and the cancer neoantigen vaccine pipeline Vaccinus, pursuing a 'Platform-to-Asset' strategy that converts discovered targets into proprietary drug candidates such as ADCs, bispecific antibodies, and cancer vaccines.

Domestic competitors in genomics include Macrogen, GC Genome, Labgenomics, and ThreeBillion, while the global sequencing tools and services market is dominated by Illumina, Thermo Fisher Scientific, and Roche.

Earnings trend

Quarterly revenue · Operating profit

₩2.6B-₩4B25Q2₩2.2B-₩2.3B25Q3₩3.1B-₩3B25Q4₩2.4B-₩2B26Q1₩3.6B-₩4.6B26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩10.1B-₩9.7B2022₩7B-₩10.1B2023₩6.5B-₩12.3B2024₩10.5B-₩11.7B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩2.6B	-₩4B	−155.8%
2025Q3	₩2.2B	-₩2.3B	−108.3%
2025Q4	₩3.1B	-₩3B	−94.3%
2026Q1	₩2.4B	-₩2B	−85.8%
2026Q2	₩3.6B	-₩4.6B	−127.4%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩10.1B	-₩9.7B	-₩9.4B	−96.0%	−21.7%	5.9%
2023	₩7B	-₩10.1B	-₩9.7B	−144.7%	−28.1%	17.5%
2024	₩6.5B	-₩12.3B	-₩12.3B	−189.9%	−55.2%	48.8%
2025	₩10.5B	-₩11.7B	-₩17.4B	−111.3%	−190.9%	332.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04

Earnings analysis

Annual revenue fell from KRW 10.08bn in 2022 to KRW 6.97bn in 2023 and KRW 6.46bn in 2024, before rebounding to KRW 10.48bn in 2025.

Profitability nonetheless worsened: operating losses ran at triple-digit KRW billion levels for four straight years, at KRW 9.68bn (2022), KRW 10.08bn (2023), KRW 12.26bn (2024), and KRW 11.67bn (2025).

Net losses attributable to owners widened every year, from KRW 9.38bn (2022) to KRW 9.68bn (2023), KRW 12.27bn (2024), and KRW 17.37bn (2025), with the 2025 net loss growing 41% year-on-year despite the revenue recovery.

On a quarterly basis, the 2025Q4 net loss of KRW 8.13bn was roughly 2.7 times the operating loss of KRW 2.96bn for the same quarter, indicating a significant non-operating drag, and a similar gap reopened in 2026Q2 with a net loss of KRW 7.75bn versus an operating loss of KRW 4.59bn.

By contrast, 2026Q1 was an exception, with revenue of KRW 2.39bn, an operating loss of KRW 2.05bn, and a net loss of KRW 2.03bn showing little divergence between the two loss measures.

Over the latest four quarters (2025Q3-2026Q2), the cumulative net loss attributable to owners reached KRW 20.36bn, already exceeding the full-year 2025 net loss of KRW 17.37bn.

Operating cash flow remained negative for four consecutive years at KRW -12.01bn (2022), KRW -8.13bn (2023), KRW -10.67bn (2024), and KRW -7.08bn (2025), though the outflow has gradually narrowed.

On the balance sheet, equity shrank from KRW 43.27bn in 2022 to KRW 9.10bn in 2025 while liabilities surged from KRW 2.56bn to KRW 30.25bn, pushing the debt ratio from 5.9% to 332.3%-a strain expected to ease following the convertible preferred share investment completed in March 2026.

Industry analysis

The domestic NGS-based genomic testing market has grown rapidly, particularly in liquid biopsy, with the liquid biopsy market growing at a 23% compound annual rate from KRW 17.8bn in 2013 to KRW 37.6bn in 2017, and projected to reach roughly KRW 105.1bn by 2022.

Globally, however, Illumina, Thermo Fisher Scientific, and Roche account for most of the market, while in Korea, GC Genome, Macrogen, Labgenomics, Geninus, and ThreeBillion continue to expand.

Single-cell and spatial transcriptomics analysis is expanding in scope alongside the spread of precision medicine, moving beyond diagnostics into drug target discovery and companion diagnostics development.

While most domestic peers rely largely on research-service and diagnostic revenue, Geninus has chosen a differentiated path of accumulating single-cell and spatial omics data to pivot into an AI drug-discovery platform.

The company has cited the French/European single-cell and spatial omics AI company OWKIN as a reference point for its growth strategy.

Still, most domestic genomic analysis firms remain small in scale with fragile earnings structures, leaving the sector broadly dependent on capital-market funding, with government biohealth deregulation cited as a key swing factor for market expansion.

Geninus is not classified among the top-revenue players domestically, but its dual push into the Japanese market and an AI-platform transition sets it apart from peers in terms of strategic positioning.

Outlook

The company's near-term growth engine is its Japanese subsidiary GxD. GxD has secured roughly KRW 10bn in stable revenue over three years by participating in the SCRUM-Japan MONSTAR-Screen-3 cancer research project.

Management has stated that, based on the expansion of its Japanese business, it expects GxD's 2026 revenue to grow more than 80% year-on-year.

In March 2026, GxD signed and began executing an IntelliMed-based project contract with a large Japanese pharmaceutical company, described as the first of a three-stage collaboration process with potential for follow-on agreements and longer-term partnership.

By April, discussions with another Japanese pharmaceutical company for a separate new contract were reported to be at an advanced stage.

On the financial side, the company raised KRW 20bn in March 2026 through a convertible preferred share issuance from KB Investment and Company K Partners, exiting capital impairment status and removing the risk of administrative-issue designation tied to pre-tax continuing losses.

The proceeds are earmarked for research and development of drug candidates derived from targets discovered through the IntelliMed platform.

Whether this expansion strategy translates into actual revenue and profitability improvement will take time, and whether the guided GxD growth and additional Japanese contracts materialize into confirmed disclosures will be a key variable shaping future results.

Valuation

PER

—

PBR

1.4×

ROE

-72.4%

EPS

-₩598

BPS

₩1,170

Dividend per share

₩0

Geninus continues to post net losses over the latest four quarters, making profit-based valuation metrics difficult to apply.

Price-to-book readings vary meaningfully across data providers, reflecting the sharp change in capital structure following the steep decline in equity through 2025 and the large convertible preferred share issuance in early 2026. The company has no recent dividend payment history given its sustained losses.

Historical trading patterns show the stock has been prone to sharp swings around individual events such as earnings releases, Japanese contract announcements, and conference presentations, suggesting the shares tend to react more to business milestones than to conventional valuation bands.

Investors may want to monitor both the direction of loss narrowing and the pace of financial stabilization following the recent capital injection.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04

Bull factors

Expanding Japan GxD Order Book

Through its Japanese subsidiary GxD, Geninus has been widening its overseas revenue base via the SCRUM-Japan project and contracts with multiple large pharmaceutical companies.

The company projects GxD revenue will grow more than 80% year-on-year in 2026, and additional contract discussions with Japanese pharma companies were reported in March-April 2026. Having established references in Japan's high-barrier pharmaceutical market could serve as a springboard for further order growth.

Capital Injection Eases Financial Risk

In March 2026, Geninus secured a KRW 20bn convertible preferred share investment from KB Investment and Company K Partners, resolving capital impairment and administrative-issue designation risk. The proceeds are planned for drug candidate research and development, easing near-term liquidity concerns.

The participation of institutional investors can be read as an external endorsement of the platform's competitiveness.

Pivot to Platform-Based Drug Discovery

The company is pursuing a 'Platform-to-Asset' strategy built on its single-cell and spatial omics database CASOD and its AI platform IntelliMed, attempting to transition from a service provider into a drug-discovery company.

Technology partnerships are also expanding, including the enhancement of SpaceInsight through collaboration with AWS and cooperation with 10x Genomics. Presentations at international conferences such as AACR and ESMO serve as opportunities for external validation of its technology.

Bear factors

Delayed Profitability Improvement

Even as revenue recovered in 2025, both operating and net losses widened, and the cumulative net loss over the latest four quarters has already surpassed the full-year 2025 loss. Revenue growth has not translated directly into earnings improvement, raising questions about the pace of cost structure improvement. Concrete evidence for a specific breakeven timeline remains limited.

Rapid Shifts in Capital Structure

Equity fell from KRW 43.27bn in 2022 to KRW 9.10bn in 2025, while the debt ratio surged from 5.9% to 332.3% over the same period.

This was partly eased by the early-2026 convertible preferred share issuance, but a structure that repeatedly relies on external capital raising carries the risk of further dilution for existing shareholders. A similar pattern could recur if additional funding is needed going forward.

Execution Risk in the Growth Strategy

The expansion of Japanese revenue and the Platform-to-Asset strategy remain at an early stage, and it has not yet been verified whether the announced contracts are large enough to meaningfully improve overall company earnings.

Moving from target discovery to clinical entry requires substantial time and additional funding. With relatively high dependence on a small number of projects, any delay or reduction in contracts could slow the pace of earnings improvement.

Risk factors

Financial Risk

The debt ratio surged to 332.3% at the end of 2025, and operating cash flow has been negative for four consecutive years, indicating heavy reliance on external funding.

While the March 2026 capital injection resolved the capital impairment status, the possibility of additional future fundraising cannot be ruled out given the scale of ongoing losses. Outstanding convertible bonds and preferred shares also represent potential dilution as share counts could rise going forward.

Customer and Revenue Concentration Risk

A significant portion of overseas revenue growth is concentrated in GxD's SCRUM-Japan project and a small number of large pharmaceutical company contracts. In a structure with high dependence on specific projects or clients, failure to renew contracts or changes in terms could directly affect results.

The relatively small domestic revenue base is also a factor worth monitoring from a revenue-diversification perspective.

Business Model Transition Risk

The Platform-to-Asset strategy of transitioning from a service company into a drug developer requires lengthy R&D and substantial capital before reaching clinical stages. Whether discovered targets will translate into actual licensing deals or proprietary pipeline outcomes has not yet been validated.

Given the inherently high failure rate in drug development, it may take considerable time before investment outcomes become visible.

What to watch next

Around November 2026 (Q3 report filing)
Once 2026Q3 results are disclosed, it will be worth checking whether GxD's revenue growth continues, whether losses narrow, and whether the gap between operating and net losses shrinks as it did in 2026Q1.
During the second half of 2026
It should be confirmed whether the additional Japanese pharmaceutical contract reported in April 2026 is formally disclosed via DART, and what the finalized contract size and terms turn out to be.
Around March 2027 (2026 annual report filing)
It will be important to verify whether the company's guidance for GxD's 2026 revenue to grow more than 80% was actually achieved, and whether full-year operating and net losses narrowed versus 2025.
From March 26, 2027 onward
This marks the start of the conversion request period for the convertible preferred shares issued in March 2026, making it worth tracking conversion progress and resulting changes in outstanding share count.

Overall view

Geninus saw operating and net losses widen even as revenue recovered in 2025, with equity declining and the debt ratio spiking, adding to financial strain.

The March 2026 KRW 20bn convertible preferred share investment resolved capital impairment and administrative-issue designation risk for now, but the loss trend itself has continued, with the cumulative net loss over the latest four quarters already exceeding the full-year 2025 figure.

The core growth driver is Japanese subsidiary GxD, which is guided to grow revenue more than 80% in 2026 on the back of the SCRUM-Japan project and multiple large pharmaceutical contracts, with further contract discussions underway.

At the same time, the 'Platform-to-Asset' strategy of shifting from a service company to an AI drug-discovery firm remains at an early stage, and whether it will translate into actual drug candidate achievements or licensing deals has not been verified.

Investors will want to watch the pace of earnings improvement in coming quarters, whether Japanese contracts materialize into formal disclosures, and the degree of financial stabilization following the recent capital raise. This is a period where business expansion and financial risk coexist, warranting balanced observation.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.